BioWorld

Feb. 16, 2006

Anadys’ Phase II Data Strong With HBV Nucleotide Analogue

Anadys Pharmaceuticals Inc. and South Korean co-developer L.G. Life Sciences Ltd. reported strong data from a Phase II trial with ANA380 against chronic hepatitis B virus, a compound for which Novartis AG holds a license option. (BioWorld Today) Read More

FDA Says Critical Path Key To Speeding Development

Australia’s G2 Enters Novo Deal Valued At Up To $102M

BioWorld Publishing New Biodefense Resource Guide

Clinic Roundup

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...